Newsroom

Sorted by: Latest

-

Qnity to Present at Deutsche Bank’s 2026 Technology Conference

WILMINGTON, Del.--(BUSINESS WIRE)--Qnity Electronics, Inc. (“Qnity”) (NYSE: Q), a premier technology solutions leader across the semiconductor value chain, today announced that Jon Kemp, Qnity’s Chief Executive Officer, will participate in a fireside chat at Deutsche Bank’s 2026 Technology Conference on August 26, at 4:05 p.m. PT. A live webcast of the presentation will be available at Events | Qnity Electronics, Inc. (Q). A replay of the webcast will be available following the conclusion of th...
-

LifeMine Raises $263 Million to Accelerate the Clinical Development of LIFE-001, a Structurally and Mechanistically Novel Calcineurin Activation Inhibitor Designed to Transform Organ Transplantation

WATERTOWN, Mass.--(BUSINESS WIRE)--LifeMine Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering Top-Down Drug Discovery™, which leverages digital genomic search technology from fungi to source next-generation precision medicines, today announced $263 million in financing to accelerate the clinical development of the company’s lead program, LIFE-001, and advance its pipeline of novel transplantation and immunology therapies. LIFE-001 is a structurally and mechanistically nov...
-

Cresco Labs Reports Second Quarter 2026 Financial Results; Delivers $173 Million in Revenue and $40 Million in Adjusted EBITDA

CHICAGO--(BUSINESS WIRE)--Cresco Labs Reports Second Quarter 2026 Financial Results; Delivers $173 Million in Revenue and $40 Million in Adjusted EBITDA...
-

Graham Corporation Reports First Quarter Fiscal 2027 Results

BATAVIA, N.Y.--(BUSINESS WIRE)--Graham Corporation (NYSE: GHM) (“GHM” or the “Company”), a global leader in the design and manufacture of mission critical fluid, power, heat transfer, vacuum, and advanced mixing technologies for the Defense, Space, and Energy & Process industries, today reported financial results for its first quarter for the fiscal year ending March 31, 2027 (“fiscal 2027”). Graham’s President and Chief Executive Officer, Matthew J. Malone stated, “Our first quarter result...
-

Vontier Reports Strong Second Quarter Results and Raises Full Year Adjusted EPS Guidance

RALEIGH, N.C.--(BUSINESS WIRE)--Vontier Reports Strong Second Quarter Results and Raises Full Year Guidance...
-

Palladyne AI Reports Second Quarter 2026 Results

SALT LAKE CITY--(BUSINESS WIRE)--Palladyne AI Corp. (NASDAQ: PDYN and PDYNW) (“Palladyne AI” or “the Company”), a U.S.-based aerospace, defense and industrial technology company delivering embodied AI-powered collaborative autonomy solutions, advanced avionics, precision-manufactured components, UAVs, and advanced aerospace engineering services, today announced financial results for the second quarter ended June 30, 2026. Ben Wolff, President and Chief Executive Officer of Palladyne AI, comment...
-

Molson Coors Beverage Company présente ses résultats pour le deuxième trimestre de 2026

GOLDEN, Colorado et MONTRÉAL--(BUSINESS WIRE)--Molson Coors Beverage Company (« MCBC », « Molson Coors » ou la « Société ») (NYSE : TAP, TAP.A; TSX : TPX.A, TPX.B) a annoncé aujourd’hui ses résultats pour le deuxième trimestre de 2026. FAITS SAILLANTS FINANCIERS DU DEUXIÈME TRIMESTRE DE 20261 Chiffre d’affaires net en baisse de 3,3 pour cent sur la base des résultats déclarés, et de 3,6 pour cent en devises constantes. Bénéfice avant impôt, selon les PCGR des États-Unis, de 283,1 millions de do...
-

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department of Verterans Affairs (VA) on a multi-site randomized controlled clinical trial. The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-resistant depression (TRD) in veterans, including those with concurrent post-trauma...
-

Molson Coors Beverage Company Reports 2026 Second Quarter Results

GOLDEN, Colo. & MONTRÉAL--(BUSINESS WIRE)--Molson Coors Beverage Company Reports 2026 Second Quarter Results...
-

Opal Therapeutics Secures $1.25M NSF SBIR Phase II Award to Accelerate Women’s Health Drug Discovery

SAN FRANCISCO--(BUSINESS WIRE)--Opal Therapeutics secures a $1.25M NSF SBIR Phase II award to scale its uterine organoid platform for endometriosis and fibroid drug discovery....